Abstract
Up to 50% of patients with hepatocellular carcinoma (HCC) have the so-called “cryptogenic cirrhosis.” Most of them are affected by at least one of the condition characterizing the metabolic syndrome, as obesity or diabetes.
Recent observations found that type-2 diabetes mellitus (DM) confers a three-fold risk of HCC.
Main molecular feature of the conditions of metabolic syndrome is insulin resistance, i.e. the reduced sensitivity to insulin action and, as consequence, increased secretion of this hormone.
Insulin resistance and hyperinsulinemia influence hepatocarcinogenesis via several molecular pathways, such as phosphatase and tensin homolog (PTEN)/P13K/Akt and MAPK kinase (MAPKK).
Diabetes also seems to influence negatively the prognosis and the clinical course of HCC patients, independently from the cause of the underlying cirrhosis.
It’s well known that insulin-sensitizing drugs may reduce the incidence of HCC.
Metformin activates 5-adenosine monophosphate-activated protein kinase (AMPK), that has growth inhibition effects on human cancer cell lines via inhibition of its downstream target mammalian target of rapamycin (mTOR), and decreases the expression of Livin, a protein involved in both cell proliferation and survivalexpressed at high level in neoplastic cell.
Also thiazolidinediones seem to prevent tumor formation in the liver via the inhibition of peroxisome proliferatoractivated receptor gamma-independent regulation of nucleophosmin.
More debated is the role of sulfonylureas in decreasing HCC incidence in diabetic patients.
Further investigations are needed to define reliable indications to therapy and surveillance in patients with diabetes or insulin resistance.
Keywords: Apoptosis, diabetes, hepatocellular carcinoma, hyperinsulinemia, liver cirrhosis, metformin.
Current Diabetes Reviews
Title:The Influence of Diabetes in the Pathogenesis and the Clinical Course of Hepatocellular Carcinoma: Recent Findings and New Perspectives
Volume: 9 Issue: 5
Author(s): Antonio Facciorusso
Affiliation:
Keywords: Apoptosis, diabetes, hepatocellular carcinoma, hyperinsulinemia, liver cirrhosis, metformin.
Abstract: Up to 50% of patients with hepatocellular carcinoma (HCC) have the so-called “cryptogenic cirrhosis.” Most of them are affected by at least one of the condition characterizing the metabolic syndrome, as obesity or diabetes.
Recent observations found that type-2 diabetes mellitus (DM) confers a three-fold risk of HCC.
Main molecular feature of the conditions of metabolic syndrome is insulin resistance, i.e. the reduced sensitivity to insulin action and, as consequence, increased secretion of this hormone.
Insulin resistance and hyperinsulinemia influence hepatocarcinogenesis via several molecular pathways, such as phosphatase and tensin homolog (PTEN)/P13K/Akt and MAPK kinase (MAPKK).
Diabetes also seems to influence negatively the prognosis and the clinical course of HCC patients, independently from the cause of the underlying cirrhosis.
It’s well known that insulin-sensitizing drugs may reduce the incidence of HCC.
Metformin activates 5-adenosine monophosphate-activated protein kinase (AMPK), that has growth inhibition effects on human cancer cell lines via inhibition of its downstream target mammalian target of rapamycin (mTOR), and decreases the expression of Livin, a protein involved in both cell proliferation and survivalexpressed at high level in neoplastic cell.
Also thiazolidinediones seem to prevent tumor formation in the liver via the inhibition of peroxisome proliferatoractivated receptor gamma-independent regulation of nucleophosmin.
More debated is the role of sulfonylureas in decreasing HCC incidence in diabetic patients.
Further investigations are needed to define reliable indications to therapy and surveillance in patients with diabetes or insulin resistance.
Export Options
About this article
Cite this article as:
Facciorusso Antonio, The Influence of Diabetes in the Pathogenesis and the Clinical Course of Hepatocellular Carcinoma: Recent Findings and New Perspectives, Current Diabetes Reviews 2013; 9 (5) . https://dx.doi.org/10.2174/15733998113099990068
DOI https://dx.doi.org/10.2174/15733998113099990068 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
Call for Papers in Thematic Issues
Advancing Diabetic Wound Healing: Mechanisms and Interventions
In recent years, diabetic wounds have become a global health concern with the increase in the incidence of diabetes. Diabetic wounds are a kind of chronic and refractory ulcer. It is generally due to the microcirculatory disturbances and the reduced levels of endogenous growth factors. Delayed cutaneous wound healing is ...read more
Oxidative and inflammatory responses in the development of secondary diabetic complications
Diabetes, along with its associated secondary complications, represents a significant global health challenge, contributing significantly to morbidity and mortality. Unhealthy lifestyle habits, reduced physical activity, environmental pollutants, and stress are pivotal factors in the onset of diabetes, particularly type-2 diabetes. Poorly managed hyperglycemia can lead to various complications, including neuropathy, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MicroRNAs in the Pathobiology of Multiple Myeloma
Current Cancer Drug Targets Unravelling the Role of Infectious Agents in the Pathogenesis of Human Autoimmunity: The Hypothesis of the Retroviral Involvement Revisited
Current Molecular Medicine Effect of Selenium Enrichment of <i>Lenzites betulinus</i> and <i>Trametes hirsuta</i> Mycelia on Antioxidant, Antifungal and Cytostatics Potential
Current Pharmaceutical Biotechnology TNF-Related Apoptosis-Inducing Ligand (TRAIL): A Potential Candidate for Combined Treatment of Hematological Malignancies
Current Pharmaceutical Design DNA Methylation: A Possible Target for Current and Future Studies on Cancer?
Epigenetic Diagnosis & Therapy (Discontinued) Beyond Single Pathway Inhibition: MEK Inhibitors as a Platform for the Development of Pharmacological Combinations with Synergistic Anti-Leukemic Effects
Current Pharmaceutical Design Nitrosative Stress as a Mediator of Apoptosis: Implications for Cancer Therapy
Current Pharmaceutical Design Antiproliferative and Proapoptotic Effects of Proteasome Inhibitors and their Combination with Histone Deacetylase Inhibitors on Leukemia Cells
Cardiovascular & Hematological Disorders-Drug Targets Overview of Medicinally Important Diterpenoids Derived from Plastids
Mini-Reviews in Medicinal Chemistry Antineoplastic Activities, Apoptotic Mechanism of Action and Structural Properties of a Novel Silver(I) Chelate
Current Medicinal Chemistry The Immunomodulatory Potential of Selected Bioactive Plant-Based Compounds in Breast Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry Cancer Stem Cells: The Emerging Challenge of Drug Targeting
Current Medicinal Chemistry Editorial Review of 2012
Current Radiopharmaceuticals NMN/NaMN Adenylyltransferase (NMNAT) and NAD Kinase (NADK) Inhibitors: Chemistry and Potential Therapeutic Applications
Current Medicinal Chemistry Water and Ion Channels: Crucial in the Initiation and Progression of Apoptosis in Central Nervous System?
Current Neuropharmacology Epigenetic Remodeling of Chromatin Architecture: Exploring Tumor Differentiation Therapies in Mesenchymal Stem Cells and Sarcomas
Current Stem Cell Research & Therapy Multifunctional Radiolabeled Nanoparticles for Targeted Therapy
Current Medicinal Chemistry Role of HBV Replication in Host Cell Metabolism: A Proteomics Analysis
Current Proteomics Patented Biomarkers of Peripheral Blood for the Early Detection of Cancer
Recent Patents on Biomarkers Targeting Cyclooxygenase-2 in Hematological Malignancies: Rationale and Promise
Current Pharmaceutical Design